What's in Watson Pharmaceuticals's pipeline?

Watson Pharmaceuticals has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Watson Pharmaceuticals's portfolio?

Top competitors by shared drug class: , Covis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/watson-pharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Watson Pharmaceuticals — Portfolio Competitive Intelligence Brief

Watson Pharmaceuticals pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Sodium Ferric Gluconate Complex in Sucrose.	Sodium Ferric Gluconate Complex in Sucrose.	marketed	Parenteral Iron Replacement [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Covis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Watson Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Watson Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/watson-pharmaceuticals. Accessed 2026-05-15.